Stock Track | CorMedix Soars as Analysts Turn Bullish on Revenue and Earnings Outlook

Stock Track11-04

Shares of CorMedix Inc. (NASDAQ: CRMD) surged 5.11% on Friday, November 4th, driven by heightened optimism from Wall Street analysts regarding the biopharmaceutical company's future growth prospects.

According to the latest consensus estimates, analysts have significantly raised their revenue and earnings forecasts for CorMedix in 2025. They now anticipate the company to generate revenues of $111 million next year, reflecting a substantial increase from their previous estimate of $100 million. Additionally, the analysts expect CorMedix to report a profit of $0.45 per share in 2025, up from their earlier projection of $0.18 per share.

The upward revisions in the forecasts suggest that analysts have become more bullish on CorMedix's business prospects, likely driven by positive developments related to the company's lead product, DefenCath®, which received FDA approval in November 2023 and has been successfully launched in both inpatient and outpatient settings.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1178980738?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-04 23:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178980738","market":"us","top_or_hot":-1,"title":"Stock Track | CorMedix Soars as Analysts Turn Bullish on Revenue and Earnings Outlook","media":"Stock Track","content":"<p>Shares of CorMedix Inc. (NASDAQ: CRMD) surged 5.11% on Friday, November 4th, driven by heightened optimism from Wall Street analysts regarding the biopharmaceutical company's future growth prospects.</p>\n\n<p>According to the latest consensus estimates, analysts have significantly raised their revenue and earnings forecasts for CorMedix in 2025. They now anticipate the company to generate revenues of $111 million next year, reflecting a substantial increase from their previous estimate of $100 million. Additionally, the analysts expect CorMedix to report a profit of $0.45 per share in 2025, up from their earlier projection of $0.18 per share.</p>\n\n<p>The upward revisions in the forecasts suggest that analysts have become more bullish on CorMedix's business prospects, likely driven by positive developments related to the company's lead product, DefenCath®, which received FDA approval in November 2023 and has been successfully launched in both inpatient and outpatient settings.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CorMedix Soars as Analysts Turn Bullish on Revenue and Earnings Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CorMedix Soars as Analysts Turn Bullish on Revenue and Earnings Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-04 23:10 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of CorMedix Inc. (NASDAQ: CRMD) surged 5.11% on Friday, November 4th, driven by heightened optimism from Wall Street analysts regarding the biopharmaceutical company's future growth prospects.\n...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRMD","symbol_name":"CorMedix Inc.","start_time":0,"source_url":"","article_id":"1178980738","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178980738","pubTimestamp":1730733031,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of CorMedix Inc.  surged 5.11% on Friday, November 4th, driven by heightened optimism from Wall Street analysts regarding the biopharmaceutical company's future growth prospects.According to the latest consensus estimates, analysts have significantly raised their revenue and earnings forecasts for CorMedix in 2025. They now anticipate the company to generate revenues of $111 million next year, reflecting a substantial increase from their previous estimate of $100 million. Additionally, th","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRMD":"CorMedix Inc."},"translate_title":"分析师看好收入和盈利前景，CorMedix股价飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRMD":1},"content_text":"Shares of CorMedix Inc. (NASDAQ: CRMD) surged 5.11% on Friday, November 4th, driven by heightened optimism from Wall Street analysts regarding the biopharmaceutical company's future growth prospects.\nAccording to the latest consensus estimates, analysts have significantly raised their revenue and earnings forecasts for CorMedix in 2025. They now anticipate the company to generate revenues of $111 million next year, reflecting a substantial increase from their previous estimate of $100 million. Additionally, the analysts expect CorMedix to report a profit of $0.45 per share in 2025, up from their earlier projection of $0.18 per share.\nThe upward revisions in the forecasts suggest that analysts have become more bullish on CorMedix's business prospects, likely driven by positive developments related to the company's lead product, DefenCath®, which received FDA approval in November 2023 and has been successfully launched in both inpatient and outpatient settings.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1178980738"}